Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

In 2021, the fda approved a treatment that claims to stop Alzheimer's at the source, removing the plaques in the brain long ...

From Science.org. "T3D Therapeutics alleges that contract researchers delivered “medically impossible” results on its candidate drug. In 2023, the drug ...

CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...

Axsome Therapeutics received FDA acceptance and priority review designation for its supplemental new drug application for AXS-05, a treatment for agitation associated with Alzheimer’s disease. The FDA ...

SHANGHAI, Jan 27 (Reuters) - China's medicine regulator has ordered a halt to the import, sale and usage of a drug used to treat dementia associated with Alzheimer's disease made by India's Sun ...